Adicet Bio Files 8-K
Ticker: ACET · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1720580
| Field | Detail |
|---|---|
| Company | Adicet Bio, Inc. (ACET) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, sec-filing
TL;DR
Adicet Bio filed a routine 8-K. No major news.
AI Summary
Adicet Bio, Inc. filed an 8-K on June 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.
Why It Matters
This 8-K filing indicates Adicet Bio, Inc. is providing standard disclosures and financial information to the SEC, which is routine for public companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, not indicating any specific new risks or material events.
Key Players & Entities
- Adicet Bio, Inc. (company) — Registrant
- resTORbio, Inc. (company) — Former company name
- June 05, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Adicet Bio, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is June 05, 2024.
What is Adicet Bio, Inc.'s principal executive office address?
Adicet Bio, Inc.'s principal executive office is located at 131 Dartmouth Street, Floor 3, Boston, Massachusetts 02116.
What was Adicet Bio, Inc.'s former company name?
Adicet Bio, Inc.'s former company name was resTORbio, Inc.
What is the Commission File Number for Adicet Bio, Inc.?
The Commission File Number for Adicet Bio, Inc. is 001-38359.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-06-05 07:01:53
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma
Filing Documents
- acet-20240605.htm (8-K) — 40KB
- acet-ex99_1.htm (EX-99.1) — 12KB
- 0000950170-24-069067.txt ( ) — 167KB
- acet-20240605.xsd (EX-101.SCH) — 24KB
- acet-20240605_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 5, 2024, Adicet Bio, Inc. issued a press release titled "Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis," a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Adicet Bio, Inc. on June 5, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ADICET BIO, INC. Date: June 5, 2024 By: /s/ Nick Harvey Name: Title: Nick Harvey Chief Financial Officer